EP Wealth Advisors LLC Takes Position in Alnylam Pharmaceuticals, Inc. $ALNY

EP Wealth Advisors LLC acquired a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 998 shares of the biopharmaceutical company's stock, valued at approximately $269,000.

A number of other large investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its position in shares of Alnylam Pharmaceuticals by 2.5% in the 1st quarter. Vanguard Group Inc. now owns 13,056,605 shares of the biopharmaceutical company's stock worth $3,525,544,000 after buying an additional 323,206 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its position in shares of Alnylam Pharmaceuticals by 0.8% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 4,418,145 shares of the biopharmaceutical company's stock worth $1,192,988,000 after buying an additional 33,696 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Alnylam Pharmaceuticals by 5.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,505,168 shares of the biopharmaceutical company's stock worth $946,466,000 after buying an additional 185,783 shares during the last quarter. American Century Companies Inc. lifted its position in shares of Alnylam Pharmaceuticals by 9.8% in the 1st quarter. American Century Companies Inc. now owns 1,760,435 shares of the biopharmaceutical company's stock worth $475,353,000 after buying an additional 156,411 shares during the last quarter. Finally, Orbis Allan Gray Ltd lifted its position in shares of Alnylam Pharmaceuticals by 11.0% in the 1st quarter. Orbis Allan Gray Ltd now owns 1,634,923 shares of the biopharmaceutical company's stock worth $441,462,000 after buying an additional 162,121 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

ALNY has been the topic of several recent research reports. Raymond James Financial initiated coverage on shares of Alnylam Pharmaceuticals in a research report on Wednesday, July 30th. They issued an "outperform" rating and a $370.00 price objective on the stock. HC Wainwright reiterated a "buy" rating and issued a $570.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Tuesday, September 2nd. BMO Capital Markets lifted their price objective on shares of Alnylam Pharmaceuticals from $450.00 to $470.00 and gave the company an "outperform" rating in a research report on Friday, September 5th. Piper Sandler lifted their price objective on shares of Alnylam Pharmaceuticals from $304.00 to $449.00 and gave the company an "overweight" rating in a research report on Friday, August 1st. Finally, Citigroup lifted their price objective on shares of Alnylam Pharmaceuticals from $527.00 to $583.00 and gave the company a "buy" rating in a research report on Tuesday, September 2nd. Twenty-three equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $421.28.

Alnylam Pharmaceuticals Trading Down 0.6%

Shares of NASDAQ:ALNY traded down $2.69 during mid-day trading on Friday, hitting $465.89. The stock had a trading volume of 630,774 shares, compared to its average volume of 1,113,410. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. The company has a market cap of $61.07 billion, a PE ratio of -188.62 and a beta of 0.32. Alnylam Pharmaceuticals, Inc. has a 12-month low of $205.87 and a 12-month high of $484.21. The company's 50 day moving average is $401.46 and its 200-day moving average is $317.35.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, beating the consensus estimate of ($0.54) by $0.86. The business had revenue of $773.69 million during the quarter, compared to the consensus estimate of $633.54 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The firm's quarterly revenue was up 17.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In other news, EVP Pushkal Garg sold 1,455 shares of the business's stock in a transaction on Tuesday, August 19th. The shares were sold at an average price of $458.41, for a total value of $666,986.55. Following the completion of the sale, the executive vice president directly owned 20,221 shares in the company, valued at approximately $9,269,508.61. The trade was a 6.71% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 1,396 shares of the business's stock in a transaction on Monday, August 18th. The stock was sold at an average price of $453.27, for a total transaction of $632,764.92. Following the completion of the sale, the executive vice president owned 22,719 shares of the company's stock, valued at $10,297,841.13. The trade was a 5.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 75,594 shares of company stock valued at $33,968,256. Insiders own 1.50% of the company's stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.